AptarGroup(ATR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATR AptarGroup

Not Yet Opened 01-14 16:00:00 EST

126.85

+3.35

+2.71%

盘后126.85

+0.000.00%

18:21 EST

High127.16	Low124.11	Vol611.74K
Open124.11	D1 Closing123.50	Amplitude2.47%
Mkt Cap8.32B	Tradable Cap8.29B	Total Shares65.62M
T/O77.36M	T/O Rate0.94%	Tradable Shares65.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ATR","market":"US","secType":"STK","nameCN":"AptarGroup","latestPrice":126.85,"timestamp":1768424400000,"preClose":123.5,"halted":0,"volume":611740,"hourTrading":{"tag":"盘后","latestPrice":126.85,"preClose":126.85,"latestTime":"18:21 EST","volume":8579,"amount":1088242.51,"timestamp":1768432871500},"delay":0,"floatShares":65331322,"shares":65619154,"eps":6.228171,"marketStatus":"Not Yet Opened","change":3.35,"latestTime":"01-14 16:00:00 EST","open":124.11,"high":127.16,"low":124.11,"amount":77363217.999449,"amplitude":0.024696,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.228171,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768467600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":735537600000,"exchange":"NYSE","adjPreClose":123.5,"dividendRate":0.014426,"postHourTrading":{"tag":"盘后","latestPrice":126.85,"preClose":126.85,"latestTime":"18:21 EST","volume":8579,"amount":1088242.51,"timestamp":1768432871500},"volumeRatio":1.479893,"impliedVol":0.3033,"impliedVolPercentile":0.8606},"requestUrl":"/m/hq/s/ATR/tweets","defaultTab":"tweets","newsList":[{"id":"2603664382","title":"AptarGroup Inc. Highlights Pharma Leadership and Innovation in Drug Delivery Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2603664382","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603664382?lang=en_us&edition=fundamental","pubTime":"2026-01-15 00:47","pubTimestamp":1768409226,"startTime":"0","endTime":"0","summary":"AptarGroup Inc. presented an overview of its financial performance and business segments at the J.P. Morgan Healthcare Conference. The company reported $3.6 billion in total annual revenue for 2024, with 46% of sales from its Beauty segment and 33% from Pharma. Aptar Pharma, a subsidiary, generated $1.6 billion in revenue, with a diversified portfolio across proprietary drug delivery systems, injectable solutions, and active material science solutions. The company highlighted its position as a leader in precision drug dosing and dispensing, serving highly regulated markets and leveraging integrated labs and prototyping for efficient solution design. AptarGroup also outlined its market presence across Beauty, Pharma, Closures, Beverage, Home Care, Food, and Personal Care, and emphasized a balanced approach to investments and long-term growth. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artif","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL1J7R6w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0976567544.SGD","LU1261432733.SGD","BK4534","LU2242649171.HKD","LU2237443622.USD","LU2592432038.USD","LU1914381329.SGD","LU2746668974.SGD","LU1363072403.SGD","LU2237443382.USD","BK4516","LU0149725797.USD","IE00B1BXHZ80.USD","BK4533","LU1917777945.USD","LU2430703095.HKD","IE00B1XK9C88.USD","BK4581","LU1551013342.USD","LU1244550221.USD","LU0496365809.HKD","LU0215105999.USD","LU0868494617.USD","LU1244550494.USD","LU0320765646.SGD","LU0820562030.AUD","LU1668664300.SGD","BK4585","LU0868494708.USD","LU1280957306.USD","LU0820561909.HKD","LU2357305700.SGD","LU2417539215.USD","LU2211815571.USD","LU1244550577.SGD","LU0238689110.USD","LU2430703251.USD","LU2237443895.HKD","LU0048584097.USD","IE00BJTD4N35.SGD","LU0640476718.USD","LU1496350502.SGD","IE00BDRTCR15.USD","LU1629891620.HKD","LU0267386448.USD","LU0345769128.USD","ATR","LU1162221912.USD","LU0943347566.SGD","IE0034235188.USD"],"gpt_icon":0},{"id":"2603653165","title":"AptarGroup Partners with CastleVax for Phase II Intranasal COVID-19 Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2603653165","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603653165?lang=en_us&edition=fundamental","pubTime":"2026-01-14 06:00","pubTimestamp":1768341628,"startTime":"0","endTime":"0","summary":"AptarGroup Inc. has announced a collaboration with CastleVax for the Phase II clinical trial of CVAX-01, a next-generation intranasal COVID-19 vaccine candidate. Aptar’s innovative nasal vaccine delivery solutions, LuerVax and Spray Divider, are being used in the trial to assess the safety, tolerability, and immune responses of the intranasal vaccine compared to an FDA-approved injectable mRNA vaccine. This partnership highlights Aptar’s expertise in advanced drug delivery technologies and its role in supporting the development and accelerated market entry of novel immunization strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL2xLz0N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","ATR"],"gpt_icon":0},{"id":"2603529474","title":"AptarGroup Partners with Bausch and Lomb on Beat the Blink Eye Care Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2603529474","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603529474?lang=en_us&edition=fundamental","pubTime":"2026-01-13 06:00","pubTimestamp":1768255242,"startTime":"0","endTime":"0","summary":"AptarGroup Inc., a global leader in drug delivery and consumer product dosing technologies, has entered into an exclusive partnership with Bausch and Lomb to bring its new Beat the Blink eye care delivery system to market. The innovative technology is designed to improve dosing precision and enhance the patient experience by overcoming the natural blink reflex during eye drop application. This collaboration leverages Aptar’s advanced R&D capabilities and customizable solutions to address evolving needs in the eye care sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  on January 12, 2026, and is solely responsible for the information ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDLb0D5PW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","BLCO","BK4198","ATR"],"gpt_icon":0},{"id":"2602552366","title":"A Look At AptarGroup (ATR) Valuation After Ave Maria Growth Fund Highlights Undervaluation And Industry Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2602552366","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602552366?lang=en_us&edition=fundamental","pubTime":"2026-01-11 23:17","pubTimestamp":1768144652,"startTime":"0","endTime":"0","summary":"AptarGroup (ATR) has attracted fresh attention after Ave Maria Growth Fund both initiated a position and highlighted the company as a top idea, while management recently outlined dates for its 2026 quarterly earnings conference calls.\nSee our latest analysis for AptarGroup.\nAptarGroup’s recent investor attention and 2026 earnings call schedule sit against a mixed picture, with a 1-day share price return of 1.15% to US$123.85, a 90-day share price return decline of 4.89%, and a 3-year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/a-look-at-aptargroup-atr-valuation-after-ave-maria-growth-fu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/a-look-at-aptargroup-atr-valuation-after-ave-maria-growth-fu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATR.AU","ATR","BK7095","BK4126"],"gpt_icon":0},{"id":"2602770803","title":"Is AptarGroup (ATR) Quietly Reframing Its Pharma Story Around Data‑Driven Health Platforms?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602770803","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602770803?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:22","pubTimestamp":1767968546,"startTime":"0","endTime":"0","summary":"Aptar Digital Health, a division of AptarGroup, recently partnered with ŌURA to connect its Migraine Buddy app with the Oura Ring, while Ave Maria Growth Fund disclosed a new position in AptarGroup, highlighting its global dispensing technology franchise and long-term potential despite near-term challenges.\nTogether, this digital health collaboration and endorsement from a growth-focused fund underscore how AptarGroup is extending its reach beyond physical drug delivery hardware into...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/is-aptargroup-atr-quietly-reframing-its-pharma-story-around","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/is-aptargroup-atr-quietly-reframing-its-pharma-story-around","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7095","ATR","ATR.AU","BK4126"],"gpt_icon":0},{"id":"2601879363","title":"Press Release: Aptar Announces 2026 Quarterly Conference Call Dates","url":"https://stock-news.laohu8.com/highlight/detail?id=2601879363","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601879363?lang=en_us&edition=fundamental","pubTime":"2026-01-08 07:57","pubTimestamp":1767830220,"startTime":"0","endTime":"0","summary":"AptarGroup, Inc. , a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases.4 Quarter and Annual 2025 Results  February 5, 2026  February 6, 2026, at. 1 Quarter 2026 Results              April 30, 2026     May 1, 2026, at. 2 Quarter 2026 Results              July 30, 2026     July 31, 2026, at. 3 Quarter 2026 Results             October 29, 2026  October 30, 2026, at. approximately one hour and interested parties are invited to listen to a. Aptar is a global leader in drug delivery and consumer product dispensing, dosing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for man","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","ATR"],"gpt_icon":0},{"id":"2601381722","title":"AptarGroup Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2601381722","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601381722?lang=en_us&edition=fundamental","pubTime":"2026-01-08 06:00","pubTimestamp":1767823237,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  on January 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL3wBjpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATR","BK4126"],"gpt_icon":0},{"id":"2601845618","title":"AptarGroup Partners with ŌURA to Integrate Migraine Buddy with Oura Ring","url":"https://stock-news.laohu8.com/highlight/detail?id=2601845618","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601845618?lang=en_us&edition=fundamental","pubTime":"2026-01-07 06:00","pubTimestamp":1767736822,"startTime":"0","endTime":"0","summary":"AptarGroup Inc., through its subsidiary Aptar Digital Health, has announced a partnership with URA to integrate the Migraine Buddy app with the Oura Ring. This collaboration aims to provide users with deeper insights into migraine triggers by combining Migraine Buddy’s detailed symptom tracking and reporting features with continuous biometric data from the Oura Ring, such as sleep patterns, heart rate variability, and temperature trends. The integration is designed to empower individuals to better understand and manage their migraine episodes by identifying potential triggers and physiological patterns, supporting a more personalized and proactive approach to migraine care.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL3qdPMg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","ATR"],"gpt_icon":0},{"id":"2601565848","title":"AptarGroup Shares Fall After Wells Fargo Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2601565848","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601565848?lang=en_us&edition=fundamental","pubTime":"2026-01-07 04:34","pubTimestamp":1767731670,"startTime":"0","endTime":"0","summary":"AptarGroup  shares fell 1.5% in recent Tuesday trading after Wells Fargo downgraded the drug delivery device manufacturer's stock to equalweight from overweight, with a price target of $133.Trading volume stood at over 327,000 shares, compared with a daily average of about 579,000 shares.Price: 121.16, Change: -1.85, Percent Change: -1.50","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATR"],"gpt_icon":0},{"id":"2601989229","title":"AptarGroup Cut to Equal-Weight From Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2601989229","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601989229?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:49","pubTimestamp":1767703740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 06, 2026 07:49 ET (12:49 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATR"],"gpt_icon":0},{"id":"2601152892","title":"Wells Fargo Downgrades AptarGroup to Equalweight From Overweight, Price Target is $133","url":"https://stock-news.laohu8.com/highlight/detail?id=2601152892","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601152892?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:39","pubTimestamp":1767703152,"startTime":"0","endTime":"0","summary":"AptarGroup (ATR) has an average rating of overweight and mean price target of $158.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ATR"],"gpt_icon":0},{"id":"2601830476","title":"AptarGroup to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601830476","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601830476?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:00","pubTimestamp":1767650414,"startTime":"0","endTime":"0","summary":"AptarGroup Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. President and CEO Stephan Tanda is scheduled to present at 11:15 a.m. Eastern Standard Time, with Executive Vice President and CFO Vanessa Kanu and President Aptar Pharma Gael Touya also available. A live audio webcast and presentation materials will be accessible in the \"Investors\" section of the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDLVFBxc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","ATR"],"gpt_icon":0},{"id":"2595763475","title":"Aceh Tamiang Approves Land for 500 Flood Victims' Homes","url":"https://stock-news.laohu8.com/highlight/detail?id=2595763475","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595763475?lang=en_us&edition=fundamental","pubTime":"2025-12-30 10:28","pubTimestamp":1767061699,"startTime":"0","endTime":"0","summary":"TEMPO.CO, Jakarta-Deputy Regent of Aceh Tamiang, Ismail, said that he and the legislative body have agreed to release a four-hectare government-owned land for the construction of 500 units of permanent housingfor the flood victims. The land is located in Bundar Village, Karang Baru Subdistrict.\"The land release has been agreed upon. The construction will be promptly started by the Tzu Chi Buddhist Foundation, so the land must be quickly prepared,\" Ismail said on Monday, December 29, 2025, as quoted from Antara.According to Ismail, besides the land, they have proposed the release of the HGU  land of a plantation company operating in the area, for both permanent and temporary housing. This was stated in a letter from the Regent of Aceh Tamiang with the reference number: Ist/42 regarding the request for the release of the Right to Cultivate  as relocation of temporary and permanent housing land, which has been submitted to the Ministry of Agrarian and Spatial Planning  in Jakarta.","market":"us","thumbnail":"https://statik.tempo.co/data/2025/12/26/id_1449964/1449964_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/12/26/id_1449964/1449964_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2076959/aceh-tamiang-approves-land-for-500-flood-victims-homes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2076959/aceh-tamiang-approves-land-for-500-flood-victims-homes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["ATR","BK4126","BK7095","PKP.AU","ATR.AU","BK7096"],"gpt_icon":0},{"id":"2593058487","title":"Nasus Pharma Partners with Aptar France and AptarGroup for NS002 Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2593058487","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593058487?lang=en_us&edition=fundamental","pubTime":"2025-12-22 21:00","pubTimestamp":1766408432,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. has expanded its collaboration agreements with Aptar France S.A.S. and AptarGroup Inc. to support the ongoing clinical development and planned commercialization of NS002, its investigational intranasal epinephrine powder formulation. The agreements provide Nasus Pharma with access to Aptar's commercially proven Unit Dose System technology, which is expected to accelerate NS002's path to market by leveraging established regulatory, manufacturing, and supply chain capabilities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire  on December 22, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nNDL8XfzFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4126","NSRX","SG9999014021.USD","IE00BKPKM429.USD","ATR","NDAQ","IE00B3QW5Z07.USD","BK4588","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","LU2210149790.SGD","BK4112","SG9999014039.USD","LU0314104364.USD","BK4007","LU2095319765.USD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2592946247","title":"Aptar's Intranasal Technology to Be Used for Milestone's FDA-Approved Heart Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2592946247","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592946247?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:26","pubTimestamp":1766010360,"startTime":"0","endTime":"0","summary":"Aptar Group said its intranasal medical delivery technology will be used to administer Cardamyst, a treatment for paroxysmal supraventricular tachycardia in adults.The consumer technology company said Wednesday that its Bidose Liquid Nasal Spray System would be the mechanism to deliver Cardamyst, a drug developed by Milestone Pharmaceuticals to treat symptoms of PSVT, a condition that causes a sudden elevated heart rate.Cardamyst received Food and Drug Administration approval last week.Aptar Group said it collaborated with Milestone to build a custom delivery system with a fully integrated cap for Cardamyst, designed to prevent accidental activation or other user errors.\"This approval underscores the broadening of Aptar's drug delivery solutions for more therapeutic areas and the growing demand for nasal drug delivery,\" Aptar Pharma President Gael Touya said. \"We are pleased that our trusted and proven Bidose nasal system, combined with our protective dual-container system, is now avai","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","ATR"],"gpt_icon":0},{"id":"2592946868","title":"AptarGroup Wins FDA Approval for Bidose Nasal Delivery System in CARDAMYST Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2592946868","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592946868?lang=en_us&edition=fundamental","pubTime":"2025-12-18 06:00","pubTimestamp":1766008827,"startTime":"0","endTime":"0","summary":"AptarGroup Inc. announced that its Bidose  Liquid Nasal Spray System has been selected as the delivery mechanism for CARDAMYST  Nasal Spray, which has received approval from the U.S. Food and Drug Administration  for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia  in adults. The approval marks a collaboration between AptarGroup Inc. and Milestone Pharmaceuticals Inc., the developer of CARDAMYST, and highlights Aptar's expanding role in providing innovative drug delivery solutions for new therapeutic areas.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via Business Wire  on December 17, 2025, and is solely responsible","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL7QDrpY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIST","ATR","BK4126","BK4007"],"gpt_icon":0},{"id":"2591620458","title":"AptarGroup Chief Accounting Officer Daniel Ackerman Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591620458","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591620458?lang=en_us&edition=fundamental","pubTime":"2025-12-16 07:23","pubTimestamp":1765840983,"startTime":"0","endTime":"0","summary":"Daniel Ackerman, Chief Accounting Officer of AptarGroup Inc., reported a disposal of common shares of AptarGroup Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AptarGroup Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL3VBYhW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AptarGroup Chief Accounting Officer Daniel Ackerman Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","ATR"],"gpt_icon":0},{"id":"2590456274","title":"Did AptarGroup’s (ATR) Legal and Inventory Strains Just Challenge Its Innovation-Led Premium Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590456274","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590456274?lang=en_us&edition=fundamental","pubTime":"2025-12-11 14:20","pubTimestamp":1765434036,"startTime":"0","endTime":"0","summary":"Earlier in 2025, AptarGroup came under pressure as ongoing intellectual property litigation, inventory challenges, and softer healthcare demand raised questions about its margins and competitive positioning.\nWhat stands out is how these legal and inventory headwinds are intersecting with concerns about a premium valuation in a packaging sector already facing broad-based strain.\nNext, we'll examine how persistent intellectual property disputes may reshape AptarGroup's investment narrative...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2041000-choice2-main-header/1585186810333"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/did-aptargroups-atr-legal-and-inventory-strains-just-challen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-atr/aptargroup/news/did-aptargroups-atr-legal-and-inventory-strains-just-challen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATR.AU","BK7095","ATR","BK4126"],"gpt_icon":0},{"id":"2588096786","title":"Adisutjipto Airport Sees Passenger Growth as ATR Flights Gain Popularity","url":"https://stock-news.laohu8.com/highlight/detail?id=2588096786","media":"Tempo","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588096786?lang=en_us&edition=fundamental","pubTime":"2025-12-03 07:37","pubTimestamp":1764718634,"startTime":"0","endTime":"0","summary":"TEMPO.CO,Jakarta-Passenger traffic at Adisutjipto Airport in Yogyakarta has increased. However, the airport in Sleman Regency is more like an alternative airport after the operation of Yogyakarta International Airport  as the main airport in Yogyakarta, located in Kulon Progo Regency.Unlike YIA, which serves international flights, Adisutjipto Airport mostly operates ATR aircraft or short-haul regional passenger aircraft such as Yogyakarta-Jakarta, Yogyakarta-Karimunjawa, and other short routes.The General Manager of Adisutjipto Airport, Wibowo Cahyono Soekadi, stated that as of November, the number of passengers at Adisutjipto Airport reached 118,971, a 2 percent increase compared to 2024, which saw 116,292 passengers,\" he said on Tuesday, December 2, 2025.ATR Aircraft","market":"sg","thumbnail":"https://statik.tempo.co/data/2025/07/02/id_1409996/1409996_720.jpg","type":0,"news_type":0,"thumbnails":["https://statik.tempo.co/data/2025/07/02/id_1409996/1409996_720.jpg"],"rights":{"source":"tempo_highlight","url":"https://en.tempo.co/read/2070463/adisutjipto-airport-sees-passenger-growth-as-atr-flights-gain-popularity","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://en.tempo.co/read/2070463/adisutjipto-airport-sees-passenger-growth-as-atr-flights-gain-popularity","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tempo_highlight","symbols":["BK4126","ATR"],"gpt_icon":0},{"id":"2588705909","title":"AptarGroup Acquires Brazil-Based Pharma Packaging Firm Sommaplast","url":"https://stock-news.laohu8.com/highlight/detail?id=2588705909","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588705909?lang=en_us&edition=fundamental","pubTime":"2025-12-02 06:00","pubTimestamp":1764626422,"startTime":"0","endTime":"0","summary":"AptarGroup Inc. has acquired Sommaplast, a Brazil-based provider of oral dosing pharma packaging solutions including closures, droppers, dispensers, and dosing cups. The move is expected to strengthen Aptar's presence in Brazil and position the company to benefit from the country's fast-growing oral dosing, over-the-counter, and nutraceutical markets. Sommaplast, which has operated for over 20 years in So Paulo and employs more than 400 people, is recognized for its dosing expertise and strong customer relationships. Aptar plans to maintain Sommaplast's family-owned company culture while leveraging its global network and operational synergies to expand Sommaplast's offerings in the oral dosing pharma markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLHYFxR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATR","BK4126"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aptar.com","stockEarnings":[{"period":"1week","weight":0.0532},{"period":"1month","weight":0.0369},{"period":"3month","weight":-0.0179},{"period":"6month","weight":-0.1888},{"period":"1year","weight":-0.1795},{"period":"ytd","weight":0.0401}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0141},{"period":"3month","weight":0.045},{"period":"6month","weight":0.1},{"period":"1year","weight":0.1858},{"period":"ytd","weight":0.0124}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AptarGroup, Inc. designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. It also provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases; elastomer for injectable primary packaging components; and active material science solutions. In addition, the company offers dispensing pumps, closures, elastomeric components, and aerosol valves to the digital health solutions. It primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.017225},{"month":2,"riseRate":0.75,"avgChangeRate":0.027085},{"month":3,"riseRate":0.75,"avgChangeRate":0.026287},{"month":4,"riseRate":0.709677,"avgChangeRate":0.025156},{"month":5,"riseRate":0.666667,"avgChangeRate":0.014322},{"month":6,"riseRate":0.515152,"avgChangeRate":-0.010248},{"month":7,"riseRate":0.575758,"avgChangeRate":0.012557},{"month":8,"riseRate":0.545455,"avgChangeRate":0.008648},{"month":9,"riseRate":0.424242,"avgChangeRate":-0.015886},{"month":10,"riseRate":0.606061,"avgChangeRate":0.006242},{"month":11,"riseRate":0.818182,"avgChangeRate":0.03915},{"month":12,"riseRate":0.606061,"avgChangeRate":0.012796}],"exchange":"NYSE","name":"AptarGroup","nameEN":"AptarGroup"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AptarGroup(ATR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AptarGroup(ATR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AptarGroup,ATR,AptarGroup股票,AptarGroup股票老虎,AptarGroup股票老虎国际,AptarGroup行情,AptarGroup股票行情,AptarGroup股价,AptarGroup股市,AptarGroup股票价格,AptarGroup股票交易,AptarGroup股票购买,AptarGroup股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AptarGroup(ATR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AptarGroup(ATR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction